Spero Therapeutics Investor Relations Material

Spero Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for bacterial infections, including multi-drug-resistant bacterial infections. The company's pipeline includes both oral and intravenous antibiotic candidates designed to address serious and difficult-to-treat infections. Spero's lead programs target conditions such as urinary tract infections and hospital-acquired bacterial infections, with an emphasis on addressing the growing challenge of antibiotic resistance. The company’s research and development efforts aim to provide new therapeutic options in areas with high unmet medical needs. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.